Last reviewed · How we verify
Lenalidomide and melphalan
At a glance
| Generic name | Lenalidomide and melphalan |
|---|---|
| Also known as | Revlimid, Melphalan |
| Sponsor | Sunnybrook Health Sciences Centre |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (PHASE2)
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (PHASE2)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (PHASE3)
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (PHASE3)
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (PHASE2)
- Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenalidomide and melphalan CI brief — competitive landscape report
- Lenalidomide and melphalan updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI